Avenzo Therapeutics Presents Positive Preliminary Phase 1 Results for AVZO-1418 in Solid Tumors
Avenzo Therapeutics, a clinical-stage biotechnology company, announced positive preliminary clinical data from the Phase 1 portion of its AVENTINE-1 study for AVZO-1418. This drug is a potentially best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC) designed for locally advanced or metastatic solid tumors. The data, presented at the 38th EORTC-NCI-AACR Symposium, showed pan-tumor potential with objective responses observed across five of eight tumor types. Specifically, in 19 evaluable patients with heavily pretreated EGFR-mutant non-small cell lung cancer (NSCLC), AVZO-1418 achieved an objective response rate (ORR) of 63%. The majority of these patients were in their third line of treatment or later. The study also indicated a favorable safety profile with a low incidence of Grade 3/4 hematologic adverse events. Dr. Stephen Liu, Division Chief of Hematology/Oncology at MedStar Georgetown University Hospital, noted the encouraging activity and tolerability, particularly in EGFR-mutant NSCLC pat...